|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||63.15 - 64.60|
|52 Week Range||63.07 - 81.44|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||18.79|
|Earnings Date||Jul 27, 2023|
|Forward Dividend & Yield||2.28 (3.58%)|
|Ex-Dividend Date||Apr 06, 2023|
|1y Target Est||79.70|
Subscribe to Yahoo Finance Plus to view Fair Value for BMYLearn more
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Its hefty yield isn't the only reason to consider buying this top pharma stock.
NEW YORK, May 31, 2023--Bristol Myers Squibb to Hold R&D Day on September 14
Pharmaceutical giant Bristol-Myers Squibb has been struggling for weeks and recently broke a key support zone. In this daily bar chart of BMY, below, I can see that prices made a high in early December and turned lower. Prices held the prior low around $66 in late August and again in March but that support zone gave way last week and prices sank lower.
PRINCETON, N.J., May 30, 2023--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML
PRINCETON, N.J., May 30, 2023--US FDA Accepts for Priority Review BMS's Application for Repotrectinib
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Bristol Myers Squibb Co (NYSE: BMY) announced the first disclosure of results from the primary analysis of the pivotal TRANSCEND CLL 004 Phase 1/2 study of Breyanzi (lisocabtagene maraleucel, liso-cel) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). At a median follow-up of 21.1 months, results show that Breyanzi delivered statistically significant complete response (CR) rates, the study's primary endpoint, in 18.4% of patients in the
PRINCETON, N.J., May 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable...
PRINCETON, N.J., May 25, 2023--BMS's Breyanzi is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic....
PRINCETON, N.J., May 25, 2023--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment...
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
PRINCETON, N.J., May 25, 2023--Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
PRINCETON, N.J., May 22, 2023--Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Let's consider the case of Bristol Myers Squibb (NYSE: BMY). The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb.
The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest.
There has been no shortage of companies cutting dividends in the past year. If you're looking for some safety on the dividend front, consider Bristol Myers Squibb (NYSE: BMY), Verizon Communications (NYSE: VZ), and Coca-Cola (NYSE: KO).